Screening for Multiple Myeloma
A groundbreaking approach to identify monoclonal proteins
For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since electrophoresis was developed in 1967.
By weighing M proteins, we overcome electrophoresis’s limitations in detection and provide the most accurate understanding of a patient’s M proteins. This novel testing also helps health care providers understand their patients’ risk of progression to multiple myeloma or AL amyloidosis. This level of insight is not possible via traditional testing methods.
Which test should I order?
Enhanced Test Panel for Monoclonal Gammopathy: Finding the Fingerprint
Like a thief in the night, multiple myeloma sneaks up on people. The incurable blood cancer almost always starts as a relatively benign condition—monoclonal gammopathy of undetermined significance, or MGUS—that has no symptoms and often goes undiagnosed.
Learn more about how to order these evaluations at your institution.
Webinar - Going against the gold standard
Since the late 1960s, gel electrophoresis has been the standard of care for the detection of monoclonal proteins. Mayo Clinic’s high throughput clinical electrophoresis laboratory has stagnated in tests per full-time employee (FTE) as manual, semi-batch runs and paper result tracking are limiting our gel-based detection of monoclonal immunoglobulins (M-proteins).
Monoclonal gammopathy informative cases
Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders. View these cases of when the test should we ordered.
A test in focus: Screening and monitoring of monoclonal gammopathies
David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.Our testing is validated and developed through the use of in-house clinical studies. We also reference publications and research in each of our reports to provide clinical evidence to our interpretations.